Clinical trial design issues in mild to moderate Alzheimer disease

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.

Original languageEnglish (US)
Pages (from-to)197-201
Number of pages5
JournalCognitive and Behavioral Neurology
Volume21
Issue number4
DOIs
StatePublished - Dec 2008

Fingerprint

Alzheimer Disease
Clinical Trials
Therapeutics
Outcome Assessment (Health Care)
Pharmaceutical Preparations

Keywords

  • Alzheimer disease
  • Cholinesterase inhibitors
  • Clinical trials

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Psychiatry and Mental health
  • Cognitive Neuroscience
  • Medicine(all)

Cite this

Clinical trial design issues in mild to moderate Alzheimer disease. / Knopman, David S.

In: Cognitive and Behavioral Neurology, Vol. 21, No. 4, 12.2008, p. 197-201.

Research output: Contribution to journalArticle

@article{a48d3b0808324f2eae2a749f1888b763,
title = "Clinical trial design issues in mild to moderate Alzheimer disease",
abstract = "The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.",
keywords = "Alzheimer disease, Cholinesterase inhibitors, Clinical trials",
author = "Knopman, {David S}",
year = "2008",
month = "12",
doi = "10.1097/WNN.0b013e318190cf75",
language = "English (US)",
volume = "21",
pages = "197--201",
journal = "Cognitive and Behavioral Neurology",
issn = "1543-3633",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Clinical trial design issues in mild to moderate Alzheimer disease

AU - Knopman, David S

PY - 2008/12

Y1 - 2008/12

N2 - The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.

AB - The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.

KW - Alzheimer disease

KW - Cholinesterase inhibitors

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=61549102206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549102206&partnerID=8YFLogxK

U2 - 10.1097/WNN.0b013e318190cf75

DO - 10.1097/WNN.0b013e318190cf75

M3 - Article

VL - 21

SP - 197

EP - 201

JO - Cognitive and Behavioral Neurology

JF - Cognitive and Behavioral Neurology

SN - 1543-3633

IS - 4

ER -